CLINICAL TRIALS PROFILE FOR FINGOLIMOD

All Clinical Trials for fingolimod

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Sheffield Teaching Hospitals NHS Foundation Trust	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	University of Sao Paulo	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Uppsala University	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00273364 ↗	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Completed	Northwestern University	Phase 2	2005-11-16	Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.
NCT00289978 ↗	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	Completed	Novartis	Phase 3	2006-01-01	This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
NCT00340834 ↗	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	Completed	Novartis	Phase 3	2006-05-01	This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Clinical Trial Conditions for fingolimod

Condition Name

Condition Name for fingolimod
Intervention	Trials
Multiple Sclerosis	21
Relapsing Remitting Multiple Sclerosis	9
Relapsing-remitting Multiple Sclerosis	7
Stroke	4

Condition MeSH

Condition MeSH for fingolimod
Intervention	Trials
Multiple Sclerosis	54
Sclerosis	51
Multiple Sclerosis, Relapsing-Remitting	34
Stroke	5

Clinical Trial Locations for fingolimod

Trials by Country

Trials by Country for fingolimod
Location	Trials
United States	379
Italy	105
Canada	62
Spain	56
Australia	34

Trials by US State

Trials by US State for fingolimod
Location	Trials
Texas	18
Florida	17
Ohio	15
California	15
Illinois	14

Clinical Trial Progress for fingolimod

Clinical Trial Phase

Clinical Trial Phase for fingolimod
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	3
Phase 4	26

Clinical Trial Status

Clinical Trial Status for fingolimod
Clinical Trial Phase	Trials
Completed	40
Recruiting	13
Terminated	10

Clinical Trial Sponsors for fingolimod

Sponsor Name

Sponsor Name for fingolimod
Sponsor	Trials
Novartis Pharmaceuticals	32
Novartis	12
Sheffield Teaching Hospitals NHS Foundation Trust	3

Sponsor Type

Sponsor Type for fingolimod
Sponsor	Trials
Other	61
Industry	59
NIH	3

Fingolimod: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 20, 2026

What is the current status of clinical trials for Fingolimod?

Fingolimod, marketed as Gilenya by Novartis, is an oral sphingosine-1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis (MS). The drug has undergone extensive clinical evaluation since its approval in 2010.

As of 2023, the regulatory focus has shifted toward expanding indications and improving safety profiles. Ongoing clinical trials are primarily centered on:

• PPMS (Primary Progressive Multiple Sclerosis): Novartis launched Phase III trials (fifth iteration) evaluating Fingolimod’s efficacy for PPMS. The trials include the ORATORIO-2 study, aiming to determine if fingolimod can slow disability progression in PPMS patients.

• Secondary Progressive MS (SPMS): Several Phase II/III studies, such as TRANSFORMS-2, seek to evaluate Fingolimod’s efficacy in SPMS populations.

• Other indications: Trials include potential use for neuromyelitis optica spectrum disorder (NMOSD) and alopecia areata, although these are early-stage (Phase I/II).

Approval pathways are being pursued in multiple regions for expanded indications:

Trial/Study Name	Phase	Status	Primary Focus	Estimated Completion
ORATORIO-2	Phase III	Recruiting	PPMS efficacy	Q4 2024
TRANSFORMS-2	Phase III	Enrolling	SPMS efficacy	Q2 2024
NMOSD trial	Phase II	Recruiting	Safety & efficacy	Q3 2025

Market landscape overview

The global MS drug market reached approximately $21 billion in 2022. Fingolimod held 12% market share, approximately $2.52 billion in sales worldwide.

Major competitors include:

• Biogen's Tecfidera (Dimethyl fumarate): Leading oral MS treatment, with roughly 25% market share.
• Roche's Ocrevus (Ocrelizumab): Monoclonal antibody with 15% market share.
• Novartis' own products: Including Siponimod for SPMS and other pipeline candidates.

Recent patent expirations and biosimilar entries have threatened dominant brand positioning, leading Novartis to invest in new indications and combination therapies.

Key regional markets:

• United States: Largest revenue contributor, accounting for 55% of total sales.
• Europe: 30%, with significant growth in Germany, France, and UK.
• Asia-Pacific: Rapidly growing at 8% CAGR, driven by increased diagnosis and healthcare infrastructure improvements.

Market projections anticipate compound annual growth rate (CAGR) of 4% from 2022 to 2028, reaching approximately $27.4 billion.

Market drivers and barriers

Drivers:

• Increasing global incidence of MS, especially in young adults.
• Preference for oral therapies due to ease of administration.
• Expansion into PPMS and SPMS addresses unmet needs.

Barriers:

• Safety concerns related to fingolimod's side effects such as bradycardia, macular edema, and increased infection risk.
• Competition from high-efficacy monoclonal antibodies.
• Regulatory delays or rejection in certain regions for new indications.

Future market projections focusing on Fingolimod

Based on current clinical trials and pipeline developments, forecasts suggest:

• For MS indications: A gradual increase in market share, potentially reaching 15% of the overall MS market by 2028.
• For new indications: A significant growth driver if trials succeed; projected to contribute an additional $1.5 billion annually by 2030.
• Price points for fingolimod are expected to remain stable, around $70,000 annually per patient, with slight reductions possible through biosimilar competition.

Key considerations for investors and stakeholders

• Regulatory approvals in emerging markets can unlock new revenue streams.
• Pipeline success in PPMS and SPMS crucial for long-term growth.
• Oral drug preferences favor Fingolimod over injectable options, but safety management remains critical.

Key Takeaways

• Fingolimod continues to be an essential oral MS therapy with ongoing clinical trials targeting PPMS and SPMS.
• The global MS market is expanding, with Fingolimod gaining share amid increased competition.
• Pipeline developments and indication expansions could augment revenue streams significantly.
• Safety concerns and biosimilar competition remain barriers that could influence market penetration.
• The projected compound annual growth rate for the market is 4% from 2022 to 2028, with Fingolimod playing a continued role.

FAQs

1. What are the primary safety concerns associated with Fingolimod?
Fingolimod can cause bradycardia, macular edema, increased infection risk, and liver function abnormalities. Monitoring protocols are required during initiation and treatment.

2. How does Fingolimod compare to other oral MS therapies?
Fingolimod has demonstrated comparable efficacy to dimethyl fumarate and teriflunomide but requires more extensive cardiac monitoring at treatment initiation.

3. What is the status of Fingolimod in expanding indications?
Clinical trials for PPMS and SPMS are ongoing, with key data readouts expected between 2024 and 2025. Regulatory submissions depend on trial outcomes.

4. What regions offer the highest growth potential for Fingolimod?
The Asia-Pacific region presents high growth prospects due to rising MS diagnosis rates. Europe and emerging markets in Latin America also offer expansion opportunities.

5. How might biosimilars impact Fingolimod’s market share?
While biosimilar versions are unlikely due to Fingolimod being a small molecule, generic competition could influence cost and access, especially in price-sensitive markets.

---

References

[1] MarketWatch. (2023). Multiple sclerosis drugs market forecast.

[2] Novartis. (2023). Gilenya (fingolimod) summary of product characteristics.

[3] IQVIA. (2022). Global multiple sclerosis drug sales report.

[4] ClinicalTrials.gov. (2023). Fingolimod clinical trials for MS.

[5] GlobalData. (2023). MS market analysis and forecast.

---

Please note that clinical trial statuses and market figures are based on the latest available data as of early 2023.